Sigrun Alba Johannesdottir

Sigrun Alba Johannesdottir

Auto-generated profile, based on publicly available information

Sigrun Alba Johannesdottir

Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2013 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
SJSigrun A. Johannesdottir
Sigrun A. Johannesdottir
EHErzsébet Horváth-Puhó
Erzsébet Horváth-Puhó
ODOlaf M. Dekkers
Olaf M. Dekkers
SCSuzanne C. Cannegieter
Suzanne C. Cannegieter
JJJens Otto L. Jørgensen
Jens Otto L. Jørgensen
HSHenrik Toft Sørensen
Henrik Toft Sørensen
Venous thromboembolism (VTE) is a common disease affecting more than 1 per 1000 persons each year in Western populations.1-3 Typically, it presents as deep venous thrombosis (DVT) of the legs and can result in pulmonary embolism (PE), a potentially fatal complication.1-3

1 November 2012 in Clinical Epidemiology
Verified
Journal Article
Open access
PDF file
SJSigrun Alba Johannesdottir
Sigrun Alba Johannesdottir
EHErzsébet Horváth-Puhó
Erzsébet Horváth-Puhó
VEVera Ehrenstein
Vera Ehrenstein
MSMorten Schmidt
Morten Schmidt
LPLars Pedersen
Lars Pedersen
Henrik Toft SørensenHenrik Toft Sørensen
Henrik Toft Sørensen
The Danish health care system provides partial reimbursement of most prescription medications in Denmark. The dispensation of prescription medications is registered in administrative databases. Each time a prescription is redeemed at a pharmacy, an electronic record is generated with information related to the user, prescriber, the pharmacy, and the dispensed drug. The National Health Service gathers this information for administration of the drug reimbursement plan. Recently, this information became the basis for the establishment of a new research database, the Danish National Database of Reimbursed Prescriptions (DNDRP). In this paper, we review the content, coverage, quality, linkage, access, and research possibilities of this new database. The database encompasses the reimbursement records of all reimbursed drugs sold in community pharmacies and hospital-based outpatient pharmacies in Denmark since 2004. On average, approximately 3.5 million users are recorded in the database each year. During the coverage period, the number of annual prescription redemptions increased by 15%. Most dispensed prescriptions are in the categories “alimentary tract and metabolism”, “cardiovascular system”, “nervous system”, and “respiratory system”. Individuals are identified by the unique central personal registration (CPR) number assigned to all persons born in or immigrating to Denmark. The new database fully complies with Denmark’s Act on Processing of Personal Data, while avoiding additional restrictions imposed on data use at the Danish National Prescription Registry, administered by Statistics Denmark. Most importantly, CPR numbers are reversibly encrypted, which allows re-identification of drug users; furthermore, the data access is possible outside the servers of Statistics Denmark. These features open additional opportunities for international collaboration, validation studies, studies on adverse drug effects requiring review of medical records, studies involving contact to general practitioners, and linkage of prescription data to other clinical and research databases. The DNDRP thus is a valuable data source for pharmacoepidemiological research.

29 May 2012 in Cancer
Verified
Journal Article
Closed access
PDF file
SJSigrun Alba Johannesdottir
Sigrun Alba Johannesdottir
ECEllen T. Chang
Ellen T. Chang
FMFrank Mehnert
Frank Mehnert
MSMorten Schmidt
Morten Schmidt
AOAnne Braae Olesen
Anne Braae Olesen
HSHenrik Toft Sørensen
Henrik Toft Sørensen

1 May 2012 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
SJS. A. Johannesdottir
S. A. Johannesdottir
MSM. Schmidt
M. Schmidt
EHE. Horváth‐Puhó
E. Horváth‐Puhó
Henrik Toft SørensenHenrik Toft Sørensen
Henrik Toft Sørensen

22 February 2013 in BMC Cancer
Verified
Journal Article
Open access
PDF file
SJSigrun A Johannesdottir
Sigrun A Johannesdottir
MSMorten Schmidt
Morten Schmidt
GPGary Phillips
Gary Phillips
RGRonald Glaser
Ronald Glaser
EYEric V Yang
Eric V Yang
SLStanley Lemeshow
Stanley Lemeshow
Experimental data suggest that catecholamine hormones are involved in stimulating the aggressiveness of ovarian cancer, but few population-based studies have examined this association. We therefore conducted a population-based cohort study to examine whether ß-blockers affect mortality following ovarian cancer diagnosis.

15 May 2013 in Journal of Medical Economics
Verified
Journal Article
Closed access
SJSigrun A. Johannesdottir
Sigrun A. Johannesdottir
CCChristian F. Christiansen
Christian F. Christiansen
MJMartin Johansen
Martin Johansen
MOMorten Olsen
Morten Olsen
XXXiao Xu
Xiao Xu
JFJon P. Fryzek
Jon P. Fryzek
Health resource utilization (HRU) and outcomes associated with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) are not well described. Therefore, a population-based cohort study was conducted to characterize patients hospitalized with AECOPD with regard to HRU, mortality, recurrence, and predictors of readmission with AECOPD. Using Danish healthcare databases, this study identified COPD patients with at least one AECOPD hospitalization between 2005-2009 in Northern Denmark. Hospitalized AECOPD patients' HRU, in-hospital mortality, 30-day, 60-day, 90-day, and 180-day post-discharge mortality and recurrence risk, and predictors of readmission with AECOPD in the year following study inclusion were characterized. This study observed 6612 AECOPD hospitalizations among 3176 prevalent COPD patients. Among all AECOPD hospitalizations, median length of stay was 6 days (interquartile range [IQR] 3-9 days); 5 days (IQR 3-9) among those without ICU stay and 11 days (IQR 7-20) among the 8.6% admitted to the ICU. Mechanical ventilation was provided to 193 (2.9%) and non-invasive ventilation to 479 (7.2%) admitted patients. In-hospital mortality was 5.6%. Post-discharge mortality was 4.2%, 7.8%, 10.5%, and 17.4% at 30, 60, 90, and 180 days, respectively. Mortality and readmission risk increased with each AECOPD hospitalization experienced in the first year of follow-up. Readmission at least twice in the first year of follow-up was observed among 286 (9.0%) COPD patients and was related to increasing age, male gender, obesity, asthma, osteoporosis, depression, myocardial infarction, diabetes I and II, any malignancy, and hospitalization with AECOPD or COPD in the prior year. The study included only hospitalized AECOPD patients among prevalent COPD patients. Furthermore, information was lacking on clinical variables. These findings indicate that AECOPD hospitalizations are associated with substantial mortality and risk of recurrence.